Abstract
To help determine whether sustained attention deficits as measured with the Continuous Performance Test (CPT) are stable vulnerability indicators of schizophrenia, we compared the CPT performance of schizophrenic patients before and after treatment with risperidone or haloperidol. In this double blind trial, 56 schizophrenic patients were randomly assigned to a 12-week regimen of either risperidone or haloperidol, after a 1-week washout period. The patients undertook two sessions of the CPT (undegraded and 25% degraded) twice, one at the end of the washout period and the other at the end of the study. Thirty-eight patients completed the study, 19 in each group. Both groups experienced significant improvements in clinical symptoms, and the risperidone group showed no change in the severity of extrapyramidal symptoms. Despite those improvements, the CPT performance indexes did not change significantly from the beginning to the end of the study. These findings indicate that sustained attention deficits might be stable vulnerability indicators of schizophrenia.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Addington J, Addington D . (1997): Neurocognitive functioning in schizophrenia: A trial of risperidone versus haloperidol. Can J Psychiatry 42: 983
American Psychiatric Association. (1987): Diagnostic and Statistical Manual of Mental Disorders (Third Edition, Revised). Washington, DC, APA
Asarnow RF, MacCrimmon DJ . (1978): Residual performance deficit in clinically remitted schizophrenics: A marker of schizophrenia? J Abnorm Psychol 87: 597–608
Brockel BJ, Fowler SC . (1995): Effects of chronic haloperidol on reaction time and errors in a sustained attention task: Partial reversal by anticholinergics and by amphetamine. J Pharmacol Exp Ther 275: 1090–1098
Bushnell PJ, Oshiro WM, Padnos BK . (1997): Detection of visual signals by rats: Effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention. Psychopharmacol. 134: 230–241
Bymaster FP, Heath I, Hendrix JC, Shannon HE . (1993): Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267: 16–24
Carman J, Peuskens J, Vangeneugden A . (1995): Risperidone in the treatment of negative symptoms of schizophrenia: A meta-analysis. Int Clin Psychopharmacol 10: 207–213
Chen WJ, Hsiao CK, Hsiao L-L, Hwu H-G . (1998a): Performance of the Continuous Performance Test among community samples. Schizophr Bull 24: 163–174
Chen WJ, Liu SK, Chang C-J, Lien Y-J, Chang Y-H, Hwu H-G . (1998b): Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 155: 1214–1220
Cheng JJ, Ho H, Chang CJ, Lan SY, Hwu HG . (1996): Positive and Negative Syndrome Scale (PANSS): Establishment and reliability study of a Mandarin Chinese language version. Chinese Psychiatry 10: 251–258
Chouinard G, Ross-Chouinard A, Annable L, Jones BD . (1980): The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 7: 233
Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L . (1989): The Continuous Performance Test, identical pairs version: II. Contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 29: 65–85
Cornblatt BA, Keilp JG . (1994): Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 20: 31–46
Cornblatt BA, Obuchowski M, Schnur DB, O′Brien JD . (1997): Attention and clinical symptoms in schizophrenia. Psychiatr Quart 20: 31–46
Earle-Boyer EA, Serper MR, Davidson M, Harvey PD . (1991): Continuous performance tests in schizophrenic patients: Stimulus and medication effects on performance. Psychiatry Res 37: 47–56
Epstein JI, Keefe RSE, Roitman SL, Harvey PD, Mohs RC . (1996): Impact of neuroleptic medications on continuous performance test measures in schizophrenia. Biol Psychiatry 39: 902–905
Erickson WD, Yellin AM, Hopwood JH, Realmuto GM, Greenberg LM . (1984): The effects of neuroleptics on attention in adolescent schizophrenics. Biol Psychiatry 19: 745–753
Finkelstein JRJ, Cannon TD, Gur RE, Gur RC, Moberg P . (1997): Attentional dysfunctions in neuroleptic-naive and neuroleptic-withdrawn schizophrenic patients and their siblings. J Abnorm Psychol 106: 203–212
Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberg DR . (1993): The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162: 43–48
Harvey PD, Keefe RS, Moskowitz J, Putnam KM, Mohs RC, Davis KL . (1990): Attentional markers of vulnerability to schizophrenia: Performance of medicated and unmedicated patients and normals. Psychiatry Res 33: 179–188
Harvey PD, Keefe RSE, Mitroupolou V, Dupre R, Roitman SL, Mohs RC, Siever LJ . (1996): Information-processing markers of vulnerability to schizophrenia: Performance of patients with schizotypal and nonschizotypal personality disorders. Psychiatry Res 60: 49–56
Kay SR, Fiszbein A, Opler LA . (1987): The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276
Kay SR . (1991): Positive and Negative Syndromes in Schizophrenia: Assessment and Research. New York, Brunner/Mazel
Lenzenweger MF, Cornblatt BA, Putnick M . (1991): Schizotypy and sustained attention. J Abnorm Psychol 100: 84–89
Leysen JE, Janssen PMF, Megens AAHP, Schotte A . (1994): Risperidone: A novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55: 5–12
Liu SK, Chang C-J, Lin H-N . (1996): A double-blind study of risperidone versus haloperidol treatment in acute schizophrenic patients. Chinese Psychiatry 10: 365–376 (in Chinese)
Liu SK, Hwu H-G, Chen WJ . (1997): Clinical symptom dimensions and deficits on the Continuous Performance Test in schizophrenia. Schizophr Res 25: 211–219
McGaughy J, Sarter M . (1998): Sustained attention performance in rats with intracortical infusions of 192 IgG-saporin-induced cortical cholinergic deafferentation: Effects of Physostigmine and FG 7142. Behav Neurosci 112: 1519–1525
Mirsky AF, Delisi LE, Buchsbaum MS, Quinn OW, Schwerdt P, Siever LJ, Mann L, Weingartner H, Zec R, Sostek A, Alterman I, Revere V, Dawson SD, Zahn TP . (1984): The Genain Quadruplets: Psychological studies. Psychiatry Res 13: 77–93
Mirsky AF, Yardley SL, Jones BP, Walsh D, Kendler KS . (1995): Analysis of the attention deficit in schizophrenia: A study of patients and their relatives in Ireland. J Psychiatr Res 29: 23–42
Mussgay L, Hertwig R . (1990): Signal detection indices in schizophrenics on a visual, auditory and bimodal Continuous Performance Test. Schizophr Res 3: 303–310
Nestor PG, Faux SF, McCarley RW, Sands SF, Horvath TB, Peterson A . (1991): Neuroleptics improve sustained attention in schizophrenia: A study using signal detection theory. Neuropsychopharmacol 4: 145–149
Norusis MJ . (1986): The Statistical Package for Social Sciences (SPSS), Manual of Reference. Chicago, SPSS, Inc.
Nuechterlein KH, Dawson ME . (1984): A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 10: 300–312
Nuechterlein KH . (1991): Vigilance in schizophrenia and related disorders. In Steinhauer SR, Gruzelier JH, Zubin J (eds), Handbook of Schizophrenia, Vol 5: Neuropsychology, Psychophysiology and Information Processing. Amsterdam, Elsevier, pp 397–433
Nuechterlein KH, Dawson ME, Ventura J, Fogelson D, Gitlin M, Mintz J . (1991): Testing vulnerability models: Stability of potential vulnerability indicators across clinical state. In Häfner H, Gattaz WF (eds), Search for the Causes of Schizophrenia, Vol II. Berlin, Springer-Verlag, pp 177–191
Nuechterlein KH, Dawson ME, Gitlin M, Ventura J, Goldstein MJ, Snyder KS, Yee CM, Mintz J . (1992): Developmental processes in schizophrenic disorders: Longitudinal studies of vulnerability and stress. Schizophr Bull 18: 387–425
Nurnberger JI Jr ., Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy- Friedman J, Severe JB, Malaspina D, Reich T, collaborators from the NIMH Genetics Initiative . (1994): Diagnostic Interview for Genetic Studies: Rationale, unique features, and training. Arch Gen Psychiatry 51: 849–859
Orzack MH, Kornetsky C . (1966): Attention dysfunction in chronic schizophrenia. Arch Gen Psychiatry 14: 323–327
Orzack MH, Kornetsky C, Freeman H . (1967): The effect of daily carphenazine on attention in the schizophrenic patient. Psychopharmacologia 8: 31–38
Orzack MH, Kornetsky C . (1971): Environmental and familial predictors of attention behavior in chronic schizophrenics. J Psychiatr Res 9: 21–29
Peuskens J . (1995): Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726
Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M . (1997): Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study. Acta Psychiatr Scand 95: 40–43
Rosvold HE, Mirsky AF, Sarason I, Bransome ED Jr.,, Beck LH . (1956): A Continuous Performance Test of brain damage. J Consult Psychol 20: 343–350
Rutschmann J, Cornblatt B, Erlenmeyer-Kimling L . (1977): Sustained attention in children at risk for schizophrenia: Report on a Continuous Performance Test. Arch Gen Psychiatry 34: 571–575
Seidman LJ, Van Manen KJ, Turner WM, Gamser DM, Faraone SV, Goldstein JM, Tsuang MT . (1998): The effects of increasing resource demand on vigilance performance in adults with schizophrenia or developmental attentional/learning disorders: A preliminary study. Schizophr Res 34: 101–112
Serper MR, Bergman RL, Harvey PD . (1990): Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res 32: 281–288
Spohn HE, Lacoursiere RB, Thompson K, Coyne L . (1977): Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics. Arch Gen Psychiatry 34: 633–644
Strandburg RJ, Marsh JT, Brown WS, Asarnow RF, Guthrie D, Higa J . (1990): Event- related potential correlates of impaired attention in schizophrenic children. Biol Psychiatry 27: 1103–1115
Tracy JL, Monaco CA, Abraham G, Josiassen RC, Pollock BG . (1998): Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. J Clin Psychiatry. 59: 184–188
Van Cauteren H, Megens AHPA, Lampo A, Meuldermans W . (1996): Risperidone: An overview of animal pharmacology, toxicology and pharmacokinetics. In Kane JM, Moller H-J, Awouters F (eds), Serotonin in Antipsychotic Treatment: Mechanisms and Clinical Practice. New York, Marcel Dekker, pp 253–276
Walker E, Shaye J . (1982): Familial schizophrenia: A predictor of neuromotor and attentional abnormalities in schizophrenia. Arch Gen Psychiatry 39: 1153–1156
Wohlberg GW, Kornetsky C . (1973): Sustained attention in remitted schizophrenics. Arch Gen Psychiatry 28: 533–537
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liu, S., Chen, W., Chang, CJ. et al. Effects of Atypical Neuroleptics on Sustained Attention Deficits in Schizophrenia. Neuropsychopharmacol 22, 311–319 (2000). https://doi.org/10.1016/S0893-133X(99)00137-2
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(99)00137-2
Keywords
This article is cited by
-
Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study
BMC Psychiatry (2019)
-
Bilateral Lesions of the Habenula Induce Attentional Disturbances in Rats
Neuropsychopharmacology (2005)
-
Cognition in schizophrenia
Current Psychiatry Reports (2001)
